Digital Therapeutics Podcast with Eugene Borukhovich Digital Health Today with Eugene Borukhovich

In this final episode of Digital Therapeutics Edition, Eugene and his journalistic partner, Brian Dolan, reflect on the lessons learned, guest experts, and inspiring stories featured in season one. Brian is a journalist and the founder and lead writer of Exits & Outcomes, and in each episode, he asked the guests a pointed and challenging question about their digital solutions or their outlook on the DTx industry. 
It's been an eventful five months, Brian says -- companies have been bought, merged, and sold, and have raised impressive rounds of funding -- but there are other areas that have seen little progress since the podcast was launched.
There may be a season 2 of Digital Therapeutics Edition, but in the meantime, head over to healthxl.com/dtx to continue the conversation with Eugene and other experts.
What do you think the future of DTx will look like? 

>>Click here to read the transcript

Host Links and Resources:

Connect with Eugene Borukhovich: Twitter | LinkedIn


Follow Eugene's journey of writing his first book: Hard Pill to Swallow


Connect with YourCoach.health: Website | Twitter


Subscribe to Exits & Outcomes


Brian Dolan: Twitter | LinkedIn


HealthXL: Website | Twitter | Join an Event



Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram

Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Digital Health Today is made possible by the support of our sponsors. Thank you to:

Bayer G4A

Cedars-Sinai Accelerator

Takeda

Roche

Abhishek Shah, the CEO and founder of Wellthy Therapeutics, is driven by the challenge of improving care delivery and outcomes for serious or chronic diseases like hypertension, type 2 diabetes, and kidney disease. Abhishek decided to start Wellthy after a successful career as an investor; he was inspired by the incredible ideas of other entrepreneurs, and tired of sitting on the sidelines, decided to build something himself. 
Eugene and Abhishek talked back in December, and in that time, Wellthy has laid the groundwork for expansion throughout Asia Pacific and Europe. Eugene and Abhishek talk about his efforts to get investors to back Wellthy, the technology and regulatory landscape for DTx in South Asia, and whether Wellthy is facing competition from other industry players like Apollo during the COVID-19 pandemic.

>>Click here to read the transcript

Guest Links and Resources:

Connect with Abhishek Shah: LinkedIn | Twitter


Visit Wellthy Therapeutics: Twitter | LinkedIn | Facebook | Instagram | Website



Host Links and Resources:

Connect with Eugene Borukhovich: Twitter | LinkedIn


Follow Eugene's journey of writing his first book: Hard Pill to Swallow


Connect with YourCoach.health: Website | Twitter


Subscribe to Exits & Outcomes


Brian Dolan: Twitter | LinkedIn


HealthXL: Website | Twitter | Join an Event



Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram

Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Digital Health Today is made possible by the support of our sponsors. Thank you to:

Bayer G4A

Cedars-Sinai Accelerator

Takeda

Roche

Edward Kliphuis says his love for investing in digital health comes from his love of "playing with toys" and imagining the possible benefit to health outcomes if "damn cool" solutions are scaled significantly. 
M Ventures backs many impressive companies-- like BioLink, Sonde Health, and Akili.
In this episode, Ed talks to Eugene about M Ventures' founding philosophy (how to cut delayed feedback cycles, which M Ventures views as the biggest threat to humanity), approach to investing, and discusses some of the drivers of capital injections in the DTx space. Also, Ed offers his insight into what makes for a truly successful DTx company.

>>Click here to read the transcript

Guest Links and Resources:

Connect with Edward Kliphuis: LinkedIn


Visit Amadeus Capital Partners: Twitter | LinkedIn | Website


Visit M Ventures: LinkedIn | Website



Host Links and Resources:

Connect with Eugene Borukhovich: Twitter | LinkedIn


Follow Eugene's journey of writing his first book: Hard Pill to Swallow


Connect with YourCoach.health: Website | Twitter


Subscribe to Exits & Outcomes


Brian Dolan: Twitter | LinkedIn


HealthXL: Website | Twitter | Join an Event



Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram

Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Digital Health Today is made possible by the support of our sponsors. Thank you to:

Bayer G4A

Cedars-Sinai Accelerator

Takeda

Roche

Will Gibbs came to Octopus Ventures via a circuitous route - which interestingly, included setting up a rare breed pig farm in his native Essex. He landed in venture capital because he loves to build things - especially large-scale solutions for "taboo" or overlooked medical conditions like substance addiction, menopause, and acne. 
Will and Eugene peek underneath the hood of venture capital. They discuss Octopus Ventures' investments in companies like Big Health and Quit Genius, the ins and outs of investing in DTx solutions, whether there is a valuation bubble in the DTx space, and Will offers some advice for startups looking to raise funds.

>>Click here to read the transcript
Viewing in Apple Podcasts?
Visit our website for links to everything below: https://digitalhealthtoday.com/dtx/

Guest Links and Resources:

Connect with Will Gibbs: LinkedIn https://linkedin.com/in/willgibbs1/

Visit Octopus Ventures: Twitter | LinkedIn | Website



Host Links and Resources:

Connect with Eugene Borukhovich: Twitter | LinkedIn


Follow Eugene's journey of writing his first book: Hard Pill to Swallow


Connect with YourCoach.health: Website | Twitter


Subscribe to Exits & Outcomes


Brian Dolan: Twitter | LinkedIn


HealthXL: Website | Twitter | Join an Event



Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram

Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Digital Health Today is made possible by the support of our sponsors. Thank you to:

Bayer G4A

Cedars-Sinai Accelerator

Takeda

Roche

Ciara Clancy remembers the exact moment she decided to found Beats Medical; it was when she realized her Parkinson’s patient was 20 minutes late for metronome therapy because he was frozen at the door of the hospital, unable to take a single step. The metronome therapy, which helps Parkinson’s patients with their walking and movement, was only available in hospitals and via prescription.
So Ciara decided to bring the therapy to them.
Beats Medical turns a Parkinson’s patient’s phone into a medical device that gives live, visual feedback to help improve fine motor and gross motor skills, speech, and psychological well-being. Beats’ core technology has also been repurposed and deployed for other central nervous system (CNS) disorders and to help children cope with stress during the COVID-19 pandemic.
Eugene and Ciara talk about some exciting recent developments in Beats’ product line, the evolution of their B2C and B2B models, and how Beats’ users have consistently driven the company to create better and more effective interventions.

>>Click here to read the transcript

Guest Links and Resources:

Connect with Ciara Clancy: LinkedIn | Twitter


Visit Beats Medical Ltd: Twitter | LinkedIn | YouTube| Facebook | Website



Host Links and Resources:

Connect with Eugene Borukhovich: Twitter | LinkedIn


Follow Eugene's journey of writing his first book: Hard Pill to Swallow


Connect with YourCoach.health: Website | Twitter


Subscribe to Exits & Outcomes


Brian Dolan: Twitter | LinkedIn


HealthXL: Website | Twitter | Join an Event



Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram

Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Digital Health Today is made possible by the support of our sponsors. Thank you to:

Bayer G4A

Cedars-Sinai Accelerator

Takeda

Roche

As a former IBS sufferer, Elena Mustatea knows all too well that our standard model of healthcare does not adequately treat or support people with chronic conditions—especially digestive conditions. Elena eventually took matters into her own hands and attended a detox retreat in Thailand, which restored her physical and mental well-being and gave her the idea to start Bold Health.
Bold Health is clinically validated and science-backed, and relieves the painful, life-disrupting symptoms of chronic digestive conditions through cognitive behavioral therapy and relaxation exercises. This intervention is crucial, because as Elena points out, 75% of the population suffers from GI symptoms in any given week, and 30% of the population has a diagnosable, long-term digestive condition. Digestive and autoimmune conditions are an enormous mental health burden and disproportionately affect women.
Eugene and Elena talk about Elena’s journey from consulting and venture capital to digital therapeutics, Bold Health’s recent RCT results, and Elena’s view on how digital therapeutics and pharma could work together in the future.


>>Click here to read the transcript

Guest Links and Resources:

Connect with Elena Mustatea: LinkedIn | Twitter


Visit Bold Health: Twitter | LinkedIn | Facebook | Website



Host Links and Resources:

Connect with Eugene Borukhovich: Twitter | LinkedIn


Follow Eugene's journey of writing his first book: Hard Pill to Swallow


Connect with YourCoach.health: Website | Twitter


Subscribe to Exits & Outcomes


Brian Dolan: Twitter | LinkedIn


HealthXL: Website | Twitter | Join an Event



Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram

Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Digital Health Today is made possible by the support of our sponsors. Thank you to:

Bayer G4A

Cedars-Sinai Accelerator

Takeda

Roche